Innovative Medical Device Endothelix offers the VENDYS device, the only fully automated FDA-cleared testing solution for vascular reactivity, presenting a unique and advanced offering in the outpatient cardiometabolic health diagnostics market.

Reimbursement Advantage VENDYS testing is reimbursable under Medicare and private payers, creating opportunities to target healthcare providers seeking cost-effective, reimbursable diagnostic tools to enhance patient care.

Market Positioning Operating within the medical equipment manufacturing sector with a focus on vascular health, Endothelix can expand its reach by forming partnerships with cardiology clinics, primary care practices, and wellness centers looking to adopt non-invasive vascular testing.

Growth Potential With revenues ranging between $1M and $10M and recent technological validations, there is significant opportunity to scale sales through education about vascular health and increasing adoption of endothelial health monitoring devices.

Technological Edge Utilizing advanced tech stack components like JSON-LD and Module Federation, Endothelix can leverage digital marketing and strategic integrations to broaden visibility among healthcare providers and accelerate adoption of their testing solution.